Home › Funds › Cormorant Asset Management, LP › BBIO

Cormorant Asset Management, LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Cormorant Asset Management, LP reported holding 550,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$41.0M, representing 2.10% of its reported portfolio and ranking #16 among its reported holdings. Cormorant Asset Management, LP has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)550.00K sh
Reported value held$40.96M
Portfolio Weight2.10%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's BBIO position evolved

Cormorant Asset Management, LP first disclosed a stake in BBIO in Q3 2023 at 4,662,530 shares (US$123.0M). The position peaked in Q4 2023 at 3,344,179 shares, worth US$135.0M. Across 12 filings, Cormorant Asset Management, LP increased the stake 1 time(s), trimmed it 9 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 550,000 shares valued at US$41.0M — a reduction of -300,000 shares quarter over quarter.. Notable position changes include a 42% trim in Q2 2024 (shares were roughly flat over the following quarter), a 29% trim in Q1 2026 (shares were roughly flat over the following quarter), a 35% trim in Q2 2026 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 4.66M $122.95M New
Q4 2023 3.34M $135.00M Reduce
Q1 2024 3.20M $99.04M Reduce
Q2 2024 1.86M $47.07M Reduce
Q3 2024 1.86M $47.31M Hold
Q4 2024 1.60M $43.90M Reduce
Q1 2025 2.00M $69.14M Add
Q2 2025 1.60M $69.09M Reduce
Q3 2025 1.40M $72.72M Reduce
Q4 2025 1.20M $91.79M Reduce
Q1 2026 850.00K $63.12M Reduce
Q2 2026 550.00K $40.96M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 48 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Cormorant Asset Management, LP held BBIO?

Cormorant Asset Management, LP has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Cormorant Asset Management, LP's current position in BBIO?

As of Q2 2026, Cormorant Asset Management, LP holds 550.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $40.96M, representing 2.10% of its reported portfolio and ranking #16.

Has Cormorant Asset Management, LP been buying or selling BBIO?

In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in BBIO. The position peaked in Q4 2023 at 3.34M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.